search
Back to results

Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy

Primary Purpose

Laparoscopic; Cholecystectomy, Cholelithiasis; Bile Duct, Choledocholithiasis

Status
Recruiting
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
Indocyanine Green (ICG) administration
Sponsored by
Aristotle University Of Thessaloniki
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Laparoscopic; Cholecystectomy

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. age older than 18 years old
  2. laparoscopic cholecystectomy
  3. elective surgery

Exclusion Criteria:

  1. younger than 18 years old
  2. no consent to participate to the study
  3. history of allergic reaction to iodine products
  4. urgent or emergent cholecystectomy

Sites / Locations

  • General Hospital of Thessaloniki "G. Papanikolaou"Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Group A (standard cholangiography during surgery)

Group B (cholangiography with iv administration of icg prior to surgery)

Group C (cholangiography with direct administration of icg to the bile duct system during surgery)

Arm Description

All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.

All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).

All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.

Outcomes

Primary Outcome Measures

successful imaging of biliary system
The anatomy of the extrahepatic bile ducts will be orally determined by the surgeon and the cases in which the oral description will coincide with the findings of cholangiography or not and where there were differences will be recorded.
operation duration
minutes
intra-operative complications (bleeding, bile duct leakage, bile duct injury)
presence or absence
applicability of the intra-operatively cholangiography
yes or no
presence of bile duct stones (choledocholithiasis)
yes or no

Secondary Outcome Measures

gender
male or female
ASA score
number
age
years
body mass index
kg/m2
indication for laparoscopic cholecystectomy
yes or no
SGOT
g/dL
SGPT
g/dL
ALP
g/dL
γ-GT
g/dL
total bilirubin
mg/dL
indirect bilirubin
mg/dL
direct bilirubin
mg/dL
PT
seconds
INR
number
aPTT
seconds
urea
mg/dL
creatinine
mg/dL
CRP
mg/L
WBC
mm3/L
ESR
mm
procalcitonin
mg/dL
TNF-a
pg/ml
IL-6
pg/ml

Full Information

First Posted
May 10, 2021
Last Updated
March 9, 2022
Sponsor
Aristotle University Of Thessaloniki
Collaborators
George Papanicolaou Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04908826
Brief Title
Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy
Official Title
Comparison of Administration of Indocyanine Green (ICG) for Image-Guided Laparoscopic Cholocystectomy- A Randomized, Controlled, Prospective Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 3, 2022 (Actual)
Primary Completion Date
June 1, 2022 (Anticipated)
Study Completion Date
January 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aristotle University Of Thessaloniki
Collaborators
George Papanicolaou Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the trial is to compare the routes of administration of indocyanine green (ICG) during laparoscopic cholocystectomy.
Detailed Description
Laparoscopic cholecystectomy is now the method of choice for the treatment of symptomatic and complicated gallstones. There are two major problems that can occur during and after a laparoscopic cholecystectomy. These are the remaining stones in the bile duct and the iatrogenic injuries of the bile ducts. Iatrogenic bile duct injuries are the most difficult complication of cholecystectomy and are a clinical entity that needs multifactorial treatment as it significantly increases morbidity, mortality and overall cost. Intraoperative cholangiography is used to prevent these complications. Intraoperative cholangiography is the traditional method of identifying bile duct anatomy during laparoscopic cholecystectomy. This method has the disadvantages that both the patient and the staff are exposed to radiation, while in order to perform it, catheterization of the cystic duct must be performed, which requires surgical procedures that increase the time of the operation, while in some cases it is not technically easy. Finally, with the intraoperative cholangiography, the injuries of the bile ducts are detected, after they have taken place, therefore it helps in their timely diagnosis but does not limit the frequency of their occurrence. Indocyanine green is a sterile, anionic, water-soluble but relatively hydrophobic tricarbocyanine molecule with a molecular weight of 751.4. It was developed in 1955 at Kodak Laboratories and in 1959 was approved for clinical use by the FDA. It has the property of fluorescing, after its administration, with a maximum absorption at 800 nm after exposure to infrared lighting. Its use offers an image of high clarity and sensitivity, target imaging, with parallel low acoustic emission. Indocyanine green has the following properties and advantages, which make it an important tool in the applications of medical sciences and studies. Following intravenous administration, it binds to plasma lipoproteins with minimal escape into the interstitial space. Extremely important for its clinical use is the complete excretion through the bile, as well as the non-production of metabolic products. It has low toxicity in the absence of ionization, which in combination with the short half-life of the substance, provides safety for the patient in its use and application in medical and biomedical sciences. It has low costs that in combination with its ease of use facilitates its application. No expensive equipment or large learning curve required. Also the possibility of recurrence with re-administration intraoperatively can offer a number of applications in laparoscopic surgery. It has a low rate of side effects and interactions with other drugs and preparations, a major allergic reaction has been reported in the literature. The first clinical applications of indocyanine green were to assess cardiac function, liver function in cirrhotic patients before hepatectomy, and to examine the retinal vessels. Its use in laparoscopic cholecystectomy, as already mentioned, is based on its ability to fluoresce when exposed to infrared light and in combination with the fact that when administered intravenously it is concentrated and excreted from the bile offers the possibility of intraoperative, fluorescent cholangiography that aims to identify the elements of the Callot triangle. This study aims to demonstrate that endocyanin green cholangiography is equivalent to or better than conventional cholangiography for the diagnosis of cholelithiasis and biliary injuries. It is therefore an important clinical application that will probably facilitate surgeons both in the prevention of biliary injuries and in the intraoperative diagnosis of cholelithiasis. Patients who will undergo laparoscopic cholecystectomy will be randomly divided into 3 (three) groups. The processing of the results will be done in the appropriate way and method. A total of 240 patients will be randomized into three groups of 80. In the first group (A) classical cholangiography will be performed. In group (B) will be performed intravenous fluorescent cholangiography with indocyanine green 6 (six) hours before the start of surgery. In the third group (C) will be performed intraoperative cholangiography with direct administration of indocyanine green to the gallbladder.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Laparoscopic; Cholecystectomy, Cholelithiasis; Bile Duct, Choledocholithiasis, Stone - Biliary, Post-Op Complication, Cholangiography, Indocyanine Green, Intraoperative Complications, Bile Duct Injury

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A (standard cholangiography during surgery)
Arm Type
Active Comparator
Arm Description
All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
Arm Title
Group B (cholangiography with iv administration of icg prior to surgery)
Arm Type
Active Comparator
Arm Description
All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
Arm Title
Group C (cholangiography with direct administration of icg to the bile duct system during surgery)
Arm Type
Active Comparator
Arm Description
All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
Intervention Type
Procedure
Intervention Name(s)
Indocyanine Green (ICG) administration
Other Intervention Name(s)
laparoscopic cholecystectomy, intra-operative cholangiography, c-arm recording, iodine solution administration
Intervention Description
Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.
Primary Outcome Measure Information:
Title
successful imaging of biliary system
Description
The anatomy of the extrahepatic bile ducts will be orally determined by the surgeon and the cases in which the oral description will coincide with the findings of cholangiography or not and where there were differences will be recorded.
Time Frame
intra-operatively
Title
operation duration
Description
minutes
Time Frame
intra-operatively
Title
intra-operative complications (bleeding, bile duct leakage, bile duct injury)
Description
presence or absence
Time Frame
intra-operatively
Title
applicability of the intra-operatively cholangiography
Description
yes or no
Time Frame
intra-operatively
Title
presence of bile duct stones (choledocholithiasis)
Description
yes or no
Time Frame
intra-operatively
Secondary Outcome Measure Information:
Title
gender
Description
male or female
Time Frame
pre-operatively
Title
ASA score
Description
number
Time Frame
pre-operatively
Title
age
Description
years
Time Frame
pre-operatively
Title
body mass index
Description
kg/m2
Time Frame
pre-operatively
Title
indication for laparoscopic cholecystectomy
Description
yes or no
Time Frame
pre-operatively
Title
SGOT
Description
g/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
SGPT
Description
g/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
ALP
Description
g/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
γ-GT
Description
g/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
total bilirubin
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
indirect bilirubin
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
direct bilirubin
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
PT
Description
seconds
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
INR
Description
number
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
aPTT
Description
seconds
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
urea
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
creatinine
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
CRP
Description
mg/L
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
WBC
Description
mm3/L
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
ESR
Description
mm
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
procalcitonin
Description
mg/dL
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
TNF-a
Description
pg/ml
Time Frame
24 hours prior to surgery and 24 hours after the surgery
Title
IL-6
Description
pg/ml
Time Frame
24 hours prior to surgery and 24 hours after the surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age older than 18 years old laparoscopic cholecystectomy elective surgery Exclusion Criteria: younger than 18 years old no consent to participate to the study history of allergic reaction to iodine products urgent or emergent cholecystectomy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Savvas Simeonidis, MD, PhD(c)
Phone
698 0309611
Ext
0030
Email
simeonidissavvas@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Panagiotis Christidis, MD, MSc
Phone
6940730227
Ext
0030
Email
panagiotischristidis13@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Savvas Simeonidis, MD, PhD(c)
Organizational Affiliation
General Hospital of Thessaloniki "G. Papanikolaou", Aristotle University of Thessaloniki
Official's Role
Principal Investigator
Facility Information:
Facility Name
General Hospital of Thessaloniki "G. Papanikolaou"
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Savvas Simeonidis, MD, PhD(c)

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25309071
Citation
Costi R, Gnocchi A, Di Mario F, Sarli L. Diagnosis and management of choledocholithiasis in the golden age of imaging, endoscopy and laparoscopy. World J Gastroenterol. 2014 Oct 7;20(37):13382-401. doi: 10.3748/wjg.v20.i37.13382.
Results Reference
background
PubMed Identifier
18332976
Citation
Duca S, Bala O, Al-Hajjar N, Lancu C, Puia IC, Munteanu D, Graur F. Laparoscopic cholecystectomy: incidents and complications. A retrospective analysis of 9542 consecutive laparoscopic operations. HPB (Oxford). 2003;5(3):152-8. doi: 10.1080/13651820310015293.
Results Reference
background
PubMed Identifier
23008571
Citation
Al-Mulhim AA. Current trends in laparoscopic cholecystectomy. J Family Community Med. 1997 Jul;4(2):33-40.
Results Reference
background
PubMed Identifier
22986769
Citation
Duncan CB, Riall TS. Evidence-based current surgical practice: calculous gallbladder disease. J Gastrointest Surg. 2012 Nov;16(11):2011-25. doi: 10.1007/s11605-012-2024-1. Epub 2012 Sep 18.
Results Reference
background
PubMed Identifier
22577366
Citation
Alander JT, Kaartinen I, Laakso A, Patila T, Spillmann T, Tuchin VV, Venermo M, Valisuo P. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging. 2012;2012:940585. doi: 10.1155/2012/940585. Epub 2012 Apr 22.
Results Reference
background
PubMed Identifier
25303914
Citation
Boni L, David G, Mangano A, Dionigi G, Rausei S, Spampatti S, Cassinotti E, Fingerhut A. Clinical applications of indocyanine green (ICG) enhanced fluorescence in laparoscopic surgery. Surg Endosc. 2015 Jul;29(7):2046-55. doi: 10.1007/s00464-014-3895-x. Epub 2014 Oct 11.
Results Reference
background
PubMed Identifier
30651756
Citation
Ambe PC, Plambeck J, Fernandez-Jesberg V, Zarras K. The role of indocyanine green fluoroscopy for intraoperative bile duct visualization during laparoscopic cholecystectomy: an observational cohort study in 70 patients. Patient Saf Surg. 2019 Jan 12;13:2. doi: 10.1186/s13037-019-0182-8. eCollection 2019.
Results Reference
background
PubMed Identifier
28316935
Citation
Chu W, Chennamsetty A, Toroussian R, Lau C. Anaphylactic Shock After Intravenous Administration of Indocyanine Green During Robotic Partial Nephrectomy. Urol Case Rep. 2017 Mar 10;12:37-38. doi: 10.1016/j.eucr.2017.02.006. eCollection 2017 May.
Results Reference
background
PubMed Identifier
8127574
Citation
Hope-Ross M, Yannuzzi LA, Gragoudas ES, Guyer DR, Slakter JS, Sorenson JA, Krupsky S, Orlock DA, Puliafito CA. Adverse reactions due to indocyanine green. Ophthalmology. 1994 Mar;101(3):529-33. doi: 10.1016/s0161-6420(94)31303-0.
Results Reference
background

Learn more about this trial

Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy

We'll reach out to this number within 24 hrs